Welcome to the Asan Preclinical Evaluation center for cancer therapeutiX (APEX)
Asan Medical Center, Korea’s top-ranked hospital, has long been at the forefront of cancer drug development through a series of national initiatives. These include the Center for Development and Commercialization of Anti-Cancer Therapeutics (CDCAT, 2010–2015), the Technology-to-Business (T2B) Infrastructure Center for Advancing Cancer Therapeutics (CACT, 2015–2020), and the Asan Preclinical Evaluation Center for Cancer TherapeutiX (APEX, 2020–2023).
Since August 2023, with the support of the Ministry of Health and Welfare, APEX has been offering specialized preclinical research services to accelerate the development of cancer therapeutics.
Our expertise covers a comprehensive range of in vivo non-GLP and GLP safety assessments in both rodent and non-rodent models, providing thorough evaluations of pharmaceuticals and biologics.
Our dedicated scientific and professional teams design customized research programs and conduct tailored preclinical studies to ensure the success of your drug development pipeline.
APEX is dedicated to improving the clinical and commercial success of innovative therapies. We are committed to advancing Korea’s global leadership in healthcare technology (HT) and biotechnology (BT) through world-class preclinical research.